发布求助
文献互助 智能选刊 最新文献

Cardiovascular endocrinology最新文献

筛选
英文 中文
Thirteenth World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease: selected highlights, Los Angeles, California, USA, 19–21 November 2015 第十三届世界胰岛素抵抗、糖尿病和心血管疾病大会:精选要点，美国加利福尼亚州洛杉矶，2015年11月19-21日
Cardiovascular endocrinology Pub Date : 2016-03-01 DOI: 10.1097/XCE.0000000000000074
A. Krentz
{"title":"Thirteenth World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease: selected highlights, Los Angeles, California, USA, 19–21 November 2015","authors":"A. Krentz","doi":"10.1097/XCE.0000000000000074","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000074","url":null,"abstract":"Dr Sanyal described how he and his colleagues have created a multiagency discussion group that brings together the Food and Drug Administration, the European Medicines Agency, and researchers to explore and clarify the regulatory process of drugs for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) [1]. Dr Sanyal also discussed the farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic NASH (FLINT) trial of obeticholic acid, which used a ‘vanguard’ design and early termination based on interim analyses of efficacy to minimize the need for liver biopsies [1]. A 72-month study on the use of obeticholic acid in NASH is currently in progress. According to Dr Sanyal, obeticholic acid ‘could be the first drug approved for severe NASH’. However, the FLINT trial revealed safety and tolerability issues such as elevations in low-density lipoprotein-cholesterol levels and pruritis, respectively. Of note, the noninvasive FIB4 score predicted therapeutic response in this trial http://www.hepa titisc.uw.edu/page/clinical-calculators/fib-4.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"40 7 1","pages":"33-34"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76756598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test. 运动应激试验后炎症标志物YKL-40逐渐降低。
Cardiovascular endocrinology Pub Date : 2016-03-01 Epub Date: 2016-01-04 DOI: 10.1097/XCE.0000000000000073
Naja Dam Mygind, Anna Axelsson, Martin H Ruwald, Morten Dalsgaard, Rolf Steffensen, Kasper Iversen, Julia S Johansen, Jens Kastrup
{"title":"The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test.","authors":"Naja Dam Mygind,&nbsp;Anna Axelsson,&nbsp;Martin H Ruwald,&nbsp;Morten Dalsgaard,&nbsp;Rolf Steffensen,&nbsp;Kasper Iversen,&nbsp;Julia S Johansen,&nbsp;Jens Kastrup","doi":"10.1097/XCE.0000000000000073","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000073","url":null,"abstract":"<p><strong>Background: </strong>Serum YKL-40 is an inflammatory biomarker associated with disease activity and mortality in diseases characterized by inflammation such as coronary artery disease (CAD). Exercise has a positive effect on CAD, possibly mediated by a decreased inflammatory activity. This study aimed to compare serial measurements of serum YKL-40 before and after exercise in patients with stable CAD versus controls.</p><p><strong>Materials and methods: </strong>Eleven patients with stable CAD verified by coronary angiography (>70% stenosis) and 11 patients with a computer tomography angiography with no stenosis or calcification (calcium score=0) (controls) performed a standard clinical maximal exercise test. Serum YKL-40 was measured before exercise, immediately after exercise, and every hour for 6 h.</p><p><strong>Results: </strong>Cardiovascular risk factors were more prevalent among the CAD patients compared with the controls. CAD patients had higher serum concentration of YKL-40 at baseline compared with controls, median (interquartile range) 94 (52-151) versus 57 (45-79) μg/l. Serum YKL-40 decreased stepwise after exercise, with a median decrease of 16 (13-39) μg/l for the CAD patients and 13 (10-22) μg/l for the controls from baseline to the lowest value. Thereafter, values increased again toward baseline level. Time after exercise was a significant factor for decrease in serum YKL-40 (<i>P</i><0.0001), but no difference in YKL-40 decrease over time could be demonstrated between the groups (<i>P</i>=0.12).</p><p><strong>Conclusion: </strong>Serum YKL-40 is elevated in patients with documented CAD compared with controls, and it decreases stepwise after exercise in both groups, indicating an anti-inflammatory effect of exercise independent of the presence of coronary atherosclerosis.</p>","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"5 1","pages":"21-27"},"PeriodicalIF":0.0,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34898418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
The men who stare at science 那些盯着科学看的人
Cardiovascular endocrinology Pub Date : 2015-12-01 DOI: 10.1097/xce.0000000000000055
J. Goetze, J. Rehfeld
{"title":"The men who stare at science","authors":"J. Goetze, J. Rehfeld","doi":"10.1097/xce.0000000000000055","DOIUrl":"https://doi.org/10.1097/xce.0000000000000055","url":null,"abstract":"In science, success is largely defined by publishing scientific results in relevant journals. To evaluate the quality and significance of the reported research, journals are ranked by so-called impact factors, which are surrogate measures of quality. Writing science is, however, much more than just reporting numbers and statistics, and a personal measure of career. In this regard, authorship in science has become a muddy matter, as most scientific papers in medicine and natural sciences now often have many authors. Indeed, coauthorship constitutes a large part of scientific life, and this sometimes leads to difficulties in giving the rightful people intellectual credit. In the context of modern scientific endeavors, the word ‘author’ is in danger of becoming a misnomer, as it still refers to the person writing the paper (and is distinct from an editor who shapes someone else’s original work). With scientific papers having multiple authors, it is almost impossible to accept the word ‘author’ for each individual. To use the analogy, many scientific authors, therefore, may be seen as men who stare at science rather than proper authors who do the writing.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"4 1","pages":"117-118"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87925081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical antipsychotics and metabolic syndrome 非典型抗精神病药物和代谢综合征
Cardiovascular endocrinology Pub Date : 2015-12-01 DOI: 10.1097/XCE.0000000000000063
Abigail Perez Rodriguez, K. Tajima-Pozo, Adrian Lewczuk, F. Montañés-Rada
{"title":"Atypical antipsychotics and metabolic syndrome","authors":"Abigail Perez Rodriguez, K. Tajima-Pozo, Adrian Lewczuk, F. Montañés-Rada","doi":"10.1097/XCE.0000000000000063","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000063","url":null,"abstract":"Atypical antipsychotics have become the gold standard and the first treatment option for mental illness in recent years. However, despite all the benefits provided by these drugs, a growing collection of case reports and clinical trials describing metabolic complications and body weight gain have been reported. Among atypical antipsychotic drugs, olanzapine and clozapine appear to have the highest tendency to disturb glucose metabolism compared with the other antipsychotic drugs available on the market.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"24 1","pages":"132–137"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89978585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age EMPA-REG结局:成年糖尿病患者的心血管结局试验
Cardiovascular endocrinology Pub Date : 2015-12-01 DOI: 10.1097/XCE.0000000000000069
A. Krentz
{"title":"EMPA-REG OUTCOME: cardiovascular outcome trials in diabetes come of age","authors":"A. Krentz","doi":"10.1097/XCE.0000000000000069","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000069","url":null,"abstract":"Without question, the highlight of the 2015 European Association for the Study of Diabetes conference in Stockholm was the presentation – to a capacity audience – of the results of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) OUTCOME trial. This was a highly fitting event for the Association, which celebrated its 50th anniversary last year, the aims of which are innovation and clinical relevance. Moreover, the study is an exceptional example of the clinical relevance of metabolic and cardiovascular interactions in patients with diabetes.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"51 1","pages":"115-116"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86889934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Inflammation in diabetes and cardiovascular disease: a new perspective on vitamin D 糖尿病和心血管疾病中的炎症:维生素D的新视角
Cardiovascular endocrinology Pub Date : 2015-12-01 DOI: 10.1097/XCE.0000000000000062
Lei Su, Haipeng Xiao
{"title":"Inflammation in diabetes and cardiovascular disease: a new perspective on vitamin D","authors":"Lei Su, Haipeng Xiao","doi":"10.1097/XCE.0000000000000062","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000062","url":null,"abstract":"Epidemiological studies indicate an inverse association between vitamin D level and chronic, low-grade systemic inflammatory diseases, such as type 2 diabetes mellitus and cardiovascular disease. Vitamin D signaling may interfere with transcription factors, such as nuclear factor-kappa B, which regulate the expression of inflammatory markers at several levels. In this review, the latest advances in the anti-inflammatory effects of vitamin D from experimental, observational, and small interventional studies will be discussed.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"10 1","pages":"127–131"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83461753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Conference report: 51st European Association for the Study of Diabetes (EASD) annual meeting 2015 会议报告:第51届欧洲糖尿病研究协会(EASD) 2015年年会
Cardiovascular endocrinology Pub Date : 2015-12-01 DOI: 10.1097/XCE.0000000000000070
A. Krentz
{"title":"Conference report: 51st European Association for the Study of Diabetes (EASD) annual meeting 2015","authors":"A. Krentz","doi":"10.1097/XCE.0000000000000070","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000070","url":null,"abstract":"Five decades of progress – and counting This year 1209 abstracts were accepted out of a total of 2067 submitted. The scene for the meeting was set by the President of the European Association for the Study of Diabetes (EASD) Prof. Andrew Boulton (UK), who considered the past, present and future of aspects of diabetes care and research. Prof. Boulton revisited the early days after the formation of the EASD when a primary aim of treating diabetes was to prevent glucosuria ‘at all costs!’ (see EMPA-REGOUTCOME trial below). The audience was reminded of the pre-haemoglobin A1c, pre-insulin pump, pre-self monitoring of blood glucose era – very much within living memory of many practising clinicians – when only three classes of glucose-lowering drugs were available: sulphonylureas, biguanides (of which only metformin has survived and indeed thrived) and insulin (bovine and porcine in various formulations with different – and generally rather suboptimal – pharmacokinetics).","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"7 1","pages":"138-140"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89698810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening subclinical coronary artery disease with noninvasive modalities in patients with diabetes 用无创方式筛查糖尿病患者的亚临床冠状动脉疾病
Cardiovascular endocrinology Pub Date : 2015-12-01 DOI: 10.1097/XCE.0000000000000056
Yanglu Zhao, N. Wong
{"title":"Screening subclinical coronary artery disease with noninvasive modalities in patients with diabetes","authors":"Yanglu Zhao, N. Wong","doi":"10.1097/XCE.0000000000000056","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000056","url":null,"abstract":"Diabetes mellitus is a global epidemic crisis as well as a major risk factor for coronary artery disease. Although several well-known noninvasive screening modalities including cardiac computed tomography, echocardiography, and myocardial perfusion imaging have been examined, controversies exist on the prognostic efficacy of these tests. Little is known with regard to the cost–benefit ratios and potential harms of radiation, and no standard screening algorithms have been established. In this review, we discuss the need and criteria for good testing methods and then summarize some of the latest evidence from either randomized or nonrandomized studies to see whether they may possibly strengthen current recommendations and extend the application of these screening methods in related guidelines. We propose, in the future, the development of newer, more sensitive screening modalities to better detect both short-term and long-term cardiovascular risk among asymptomatic patients with diabetes.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"68 21 1","pages":"120–126"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86387734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Cardiometabolic effects of testosterone in older men 睾酮对老年男性心脏代谢的影响
Cardiovascular endocrinology Pub Date : 2015-09-01 DOI: 10.1097/XCE.0000000000000050
G. Hackett
{"title":"Cardiometabolic effects of testosterone in older men","authors":"G. Hackett","doi":"10.1097/XCE.0000000000000050","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000050","url":null,"abstract":"Several long-term studies have demonstrated that low levels of total and free testosterone are associated with increased cardiovascular and all-cause mortality in older men aged over 60 years. Low levels of testosterone are most commonly manifested by erectile dysfunction, reduced sexual desire, and loss of morning erections. Increasing numbers of older men demand treatment for these bothersome problems. Recent data suggest that testosterone replacement therapy may reduce cardiovascular mortality as well as improving multiple surrogate markers for cardiovascular events. The paradox preventing the routine measurement and treatment of low testosterone in the elderly is concern that treatment might actually increase cardiovascular risk. Thankfully concerns about long-term prostate safety have virtually disappeared.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"1 1","pages":"108–113"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75986297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Defining the best candidates for testosterone replacement? 确定睾酮替代的最佳人选?
Cardiovascular endocrinology Pub Date : 2015-09-01 DOI: 10.1097/XCE.0000000000000059
Y. Krakowsky, E. Grober
{"title":"Defining the best candidates for testosterone replacement?","authors":"Y. Krakowsky, E. Grober","doi":"10.1097/XCE.0000000000000059","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000059","url":null,"abstract":"It is widely known that re-establishing physiologic levels of testosterone in symptomatic men with testosterone deficiency (TD) improves the undesirable symptoms associated with low testosterone. The indications for testosterone replacement therapy (TRT) have been evolving as research continues to find out who are the best candidates for therapy. Recently, concerns on the association of TRT and cardiovascular disease have received considerable attention. Before this, considerable attention had focused on the potential dangers of TRT and the risk of prostate cancer. The vast majority of contemporary evidence suggests that men with treated prostate cancer and no evidence of active disease are appropriate candidates for TRT in the context of symptomatic TD. Further, current evidence does not support denying TRT to symptomatic men with TD based on stable cardiac disease.","PeriodicalId":72529,"journal":{"name":"Cardiovascular endocrinology","volume":"10 1","pages":"77–82"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74415271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信